Harvard Bioscience - HBIO Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year target prices for Harvard Bioscience's stock. Their HBIO stock forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price.
View analysts price targets for HBIO or view top-rated stocks among Wall Street analysts.

Harvard Bioscience's stock was trading at $7.05 at the start of the year. Since then, HBIO stock has decreased by 51.5% and is now trading at $3.42.
View the best growth stocks for 2022 here.

Harvard Bioscience saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 365,700 shares, a decrease of 21.2% from the June 30th total of 464,000 shares. Based on an average daily volume of 308,000 shares, the short-interest ratio is currently 1.2 days. Approximately 1.0% of the shares of the company are short sold.
View Harvard Bioscience's Short Interest.

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HBIO earnings forecast.

Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 7.74% and a negative net margin of 3.03%. During the same quarter in the previous year, the firm earned $0.01 earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Harvard Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Royce & Associates LP (3.93%), AMH Equity Ltd (3.03%), Monarch Partners Asset Management LLC (1.94%), Assenagon Asset Management S.A. (0.11%), Triton Wealth Management PLLC (0.09%) and Bailard Inc. (0.07%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green, James W Green, Katherine A Eade, Thomas W Loewald and Value Fund Lp Palogic.
View institutional ownership trends.

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HBIO stock can currently be purchased for approximately $3.42.

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $141.04 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

Harvard Bioscience employs 475 workers across the globe.

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.